Drugs / AR177
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002403 | — | HIV infectious disease | Aronex Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR177 | “Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients” NCT00002403 ↗ |
| Known as | T-30177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298136 ↗ |
| Known as | Zintevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002403 ↗ |
| Route | Intravenous | “receive escalating doses of intravenous zintevir for 14 consecutive days.” NCT00002403 ↗ |